Houstonian Chris Hunt and his wife, Ashton, created MedVendor to be a search platform that features up-to-date information for case workers for patients seeking at-home care. Photo via Getty Images

Anyone who has had to Google their way to home health care knows that it’s not the best way to get effective help. That’s where MedVendor comes in.

Houstonian Chris Hunt and his wife, Ashton, created MedVendor to be a search platform that features up-to-date information for caseworkers for case workers for patients seeking at-home care.

At the height of the COVID-19 pandemic, Chris Hunt was at a loss for how to help patients. He had recently taken on a new role in wound care sales. His company would send dressings directly to patients, but finding someone who could apply and change them was a different matter.

“It was an absolute nightmare using [Google] as a resource because you had all of these out-of-date listings. So it was a 50-50 shot whether that company would even be in business… And so it would be one in every seven, one in every eight calls that I would make that I could actually get ahold of somebody that I could talk to about wound care services,” Chris Hunt recalls.

In 2020, the couple began interviewing developers to take their idea to reality. They incorporated as an LLC in 2021.

Chris Hunt calls the platform a home-care equivalent to Angie’s List or Yelp. Though it’s currently designed for users in the medical field, he says that they are working on crafting MedVendor to be used by the general public as well.

Users input the type of service they’re looking for, then can select multiple individual patient needs to further tailor the search. “It'll give you a short list from that of companies that can service those criteria. And once you've been given that list, then you can filter patient zip code as well as patient insurance plan to then whittle that search further and really get to a granular level in terms of what resources that you want to find,” Chris Hunt explains.

The couple says that their Houston location has been both a blessing and a curse for their burgeoning business, which released the MedVendor platform on October 1. Though Chris Hunt says that cutting his business’ teeth in Southeast Texas, with its expansive medical community “proves your worth and holds a ton of weight. There you can go to other markets and really capitalize.”

However, MedVendor doesn’t want to be known just as a Texas company — the Hunts hope to expand far beyond the Houston area to eventually become a household name.

Ashton Hunt, who was also in medical sales before the couple took the leap to pursue MedVendor full-time, is marketing director for the company. She adds that in Q4 of this year, they plan to release a phone app version of the platform, which will make using it even easier for medical teams.

“Ideally, a case manager or social worker, if they're working on a discharge plan for a patient, they can even be bedside with them with their phone to help find some resources to then pass along to the family or the caregiver,” Chris Hunt says.

Ultimately, the goal of the company, the couple says, is to open up possibilities for patients. By providing up-to-date, vetted information, the hope is that MedVendor will not only supply them with the care they need, but educate them in the process.

- YouTubewww.youtube.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”